Initial dose of oncolytic myxoma virus programs durable antitumor immunity independent of in vivo viral replication.

Taken together, these data suggest that the ability of oncolytic myxoma virus to immunologically reprogram treated tumors is dependent on initial viral dose. Additionally, this work could provide a possible mechanistic explanation for clinical results observed with other oncolytic viruses.